Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial

NCT02858804 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT02858804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02858804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2016
Completion date
June 30, 2020
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma